The Collaborative Ocular Tuberculosis Study (COTS)-1: A Multinational Review of 165 Patients with Tubercular Anterior Uveitis

References

• Dheda K, Barry CE 3rd, Maartens G. Tuberculosis. Lancet. 2016;387(10024):1211–1226. doi:10.1016/S0140-6736(15)00151-8.
   PubMed Web of Science ®Google Scholar
• Conant MM, Vrasich CR, Wongskhaluang JV, et al. Role of the infectious disease consultant in management of patients with tuberculosis-associated ocular inflammation. Open Forum Infect Dis. 2015;3(1):ofv195. doi:10.1093/ofid/ofv195.
   PubMedGoogle Scholar
• Agrawal R, Gunasekeran DV, Raje D, et al. Collaborative ocular tuberculosis study group. global variations and challenges with tubercular uveitis in the collaborative ocular tuberculosis study. Invest Ophthalmol Vis Sci. 2018;59(10):4162–4171. doi:10.1167/iovs.18-24102.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Abouammoh M, Al-Mezaine HS. Tuberculous uveitis. Int Ophthalmol Clin. 2010;50(2):19–39. doi:10.1097/IIO.0b013e3181d2ccb9.
   PubMedGoogle Scholar
• Gupta B, Agrawal R, Swampillai AJ, et al. Ocular manifestations of tuberculosis: an update. Expert Rev Ophthalmol. 2016;11(2):145–154. doi:10.1586/17469899.2016.1152887.
   Web of Science ®Google Scholar
• Bansal R, Gupta A, Gupta V, Dogra MR, Bambery P, Arora SK. Role of anti-tubercular therapy in uveitis with latent/manifest tuberculosis. Am J Ophthalmol. 2008;146(5):772–779. doi:10.1016/j.ajo.2008.06.011.
   PubMed Web of Science ®Google Scholar
• Agrawal R, Gunasekeran DV, Grant R, et al. Collaborative ocular tuberculosis study (COTS)–1 study group. clinical features and outcomes of patients with tubercular uveitis treated with antitubercular therapy in the collaborative ocular tuberculosis study (COTS)-1. JAMA Ophthalmol. 2017;135(12):1318–1327. doi:10.1001/jamaophthalmol.2017.4485.
   PubMed Web of Science ®Google Scholar
• Ang M, Chee SP. Controversies in ocular tuberculosis. Br J Ophthalmol. 2017;101(1):6–9. doi:10.1136/bjophthalmol-2016-309531.
   PubMed Web of Science ®Google Scholar
• Agarwal A, Agrawal R, Gunasekaran DV, et al. The collaborative ocular tuberculosis study (COTS)-1 report 3: polymerase chain reaction in the diagnosis and management of tubercular uveitis: global trends. Ocul Immunol Inflamm. 2019;27(3):465–473. doi:10.1080/09273948.2017.1406529.
   PubMed Web of Science ®Google Scholar
• Ang M, Htoon HM, Chee SP. Diagnosis of tuberculous uveitis: clinical application of an interferon-gamma release assay. Ophthalmology. 2009;116(7):1391–1396. doi:10.1016/j.ophtha.2009.02.005.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509–516.
   PubMed Web of Science ®Google Scholar
• Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357(21):2189–2194. doi:10.1056/NEJMsr077003.
   PubMed Web of Science ®Google Scholar
• Kee AR, Gonzalez-Lopez JJ, Al-Hity A, et al. therapy for intraocular tuberculosis: a systematic review and meta-analysis. Surv Ophthalmol. 2016;61(5):628–653. doi:10.1016/j.survophthal.2016.03.001.
   PubMed Web of Science ®Google Scholar
• Basu S, Nayak S, Padhi TR, Das T. Progressive ocular inflammation following anti-tubercular therapy for presumed ocular tuberculosis in a high-endemic setting. Eye (Lond). 2013;27(5):657–662. doi:10.1038/eye.2013.5.
   PubMed Web of Science ®Google Scholar
• McAllister WA, Thompson PJ, Al-Habet SM, Rogers HJ. Rifampicin reduces effectiveness and bioavailability of prednisolone. Br Med J (Clin Res Ed). 1983;286(6369):923–925. doi:10.1136/bmj.286.6369.923.
   PubMedGoogle Scholar
• Pantoja A, Kik SV, Denkinger CM. Costs of novel tuberculosis diagnostics–will countries be able to afford it? J Infect Dis. 2015;211(Suppl 2):S67–77. doi:10.1093/infdis/jiu820.
   PubMedGoogle Scholar
• Zanetti S, Bua A, Molicotti P, Maiore I, Pinna A. QuantiFERON-TB gold assay on plasma for confirmation of presumed tuberculosis-related uveitis. J Clin Microbiol. 2016;54(8):2175–2177. doi:10.1128/JCM.00848-16.
   PubMedGoogle Scholar
• Singh R, Gupta V, Gupta A. Pattern of uveitis in a referral eye clinic in north India. Indian J Ophthalmol. 2004;52:121–125.
   PubMedGoogle Scholar
• Gunasekeran DV, Gupta B, Cardoso J, Pavesio CE, Agrawal R. Visual morbidity and ocular complications in presumed intraocular tuberculosis: an analysis of 354 cases from a non-endemic population. Ocul Immunol Inflamm. 2018;26(6):865–869. doi:10.1080/09273948.2017.1296580.
   PubMed Web of Science ®Google Scholar
• Spratt A, Key T, Vivian AJ. Chronic anterior uveitis following bacille calmette-guérin vaccination: molecular mimicry in action? J Pediatr Ophthalmol Strabismus. 2008;45(4):252–253. doi:10.3928/01913913-20080701-15.
   PubMed Web of Science ®Google Scholar
• Gunasekeran DV, Agrawal R, Agarwal A, et al. COTS-1 study group. The collaborative ocular tuberculosis study (COTS)-1: a multinational review of 251 patients with tubercular retinal vasculitis. Retina. 2019;39(8):1623–1630. doi:10.1097/IAE.0000000000002194.
   PubMedGoogle Scholar
• Agrawal R, Gunasekeran DV, Agarwal A, et al. The collaborative ocular tuberculosis study (COTS)-1: a multinational description of the spectrum of choroidal involvement in 245 patients with tubercular uveitis. Ocul Immunol Inflamm. 2018;29:1–11. doi:10.1080/09273948.2018.1489061.
   Google Scholar
• Al-Qarni A, Abouammoh MA, Almousa AN, Mousa A, Abu El-Asrar AM. Presumed tuberculous uveitis in a university-based tertiary referral center in Saudi Arabia. Int Ophthalmol. 2019;39(2):317–333. doi:10.1007/s10792-017-0815-9.
   PubMedGoogle Scholar
• Ang M, Hedayatfar A, Wong W, Chee SP. Duration of anti-tubercular therapy in uveitis associated with latent tuberculosis: a case-control study. Br J Ophthalmol. 2012;96(3):332–336. doi:10.1136/bjophthalmol-2011-300209.
   PubMed Web of Science ®Google Scholar
• Khochtali S, Gargouri S, Abroug N, et al. The spectrum of presumed tubercular uveitis in Tunisia, North Africa. Int Ophthalmol. 2015;35(5):663–671. doi:10.1007/s10792-014-9992-y.
   PubMed Web of Science ®Google Scholar
• Ng KK, Nisbet M, Damato EM, Sims JL. Presumed tuberculous uveitis in non-endemic country for tuberculosis: case series from a New Zealand tertiary uveitis clinic. Clin Exp Ophthalmol. 2017 May;45(4):357–365. doi:10.1111/ceo.12881.
   PubMed Web of Science ®Google Scholar
• Agrawal R, Grant R, Gupta B, et al. What does IGRA testing add to the diagnosis of ocular tuberculosis? A Bayesian latent class analysis. BMC Ophthalmol. 2017;17(1):245. doi:10.1186/s12886-017-0597-x.
   PubMedGoogle Scholar
• Babu K, Satish V, Prakash O, Subbakrishna DK, Murthy KR. Role of the mantoux test and treatment with antitubercular therapy in a South Indian patient population of presumed intraocular tuberculosis. Ocul Immunol Inflamm. 2009;17(5):307–311. doi:10.3109/09273940902999349.
   PubMed Web of Science ®Google Scholar
• Ahn SJ, Kim KE, Woo SJ, Park KH. The usefulness of interferon-gamma release assay for diagnosis of tuberculosis-related uveitis in Korea. Korean J Ophthalmol. 2014;28(3):226–233. doi:10.3341/kjo.2014.28.3.226.
   PubMedGoogle Scholar
• Babu K, Satish V, Satish S, Subbakrishna DK, Abraham MP, Murthy KR. Utility of QuantiFERON TB gold test in a south Indian patient population of ocular inflammation. Indian J Ophthalmol. 2009;57(6):427–430. doi:10.4103/0301-4738.57147.
   PubMed Web of Science ®Google Scholar
• Campos WR, Henriques JF, Kritski AL, Curi A, Pimentel RT, Spindola de Miranda S. Tuberculous uveitis at a referral center in southeastern Brazil. J Bras Pneumol. 2008;34(2):98–102. doi:10.1590/s1806-37132008000200006.
   PubMedGoogle Scholar
• Chung CY, Li KKW. The efficacy of latent tuberculosis treatment for immunocompetent uveitis patients with a positive T-SPOT.TB test: 6-year experience in a tuberculosis endemic region. Int Ophthalmol. 2018;38(6):2273–2282. doi:10.1007/s10792-017-0716-y.
   PubMed Web of Science ®Google Scholar
• Shahidatul-Adha M, Zunaina E, Liza-Sharmini AT, et al. Ocular tuberculosis in hospital universiti sains malaysia - a case series. Ann Med Surg (Lond). 2017;24:25–30. doi:10.1016/j.amsu.2017.10.003.
   PubMedGoogle Scholar
• Agrawal R, Gonzalez-Lopez JJ, Nobre-Cardoso J, et al. Predictive factors for treatment failure in patients with presumed ocular tuberculosis in an area of low endemic prevalence. Br J Ophthalmol. 2016;100(3):348–355. doi:10.1136/bjophthalmol-2014-306474.
   PubMed Web of Science ®Google Scholar
• Cimino L, Herbort CP, Aldigeri R, Salvarani C, Boiardi L. Tuberculous uveitis, a resurgent and underdiagnosed disease. Int Ophthalmol. 2009;29(2):67–74. doi:10.1007/s10792-007-9071-8.
   PubMedGoogle Scholar
• Damato EM, Dawson S, Liu X, et al. A retrospective cohort study of patients treated with anti-tuberculous therapy for presumed ocular tuberculosis. J Ophthalmic Inflamm Infect. 2017;7(1):23. doi:10.1186/s12348-017-0141-4.
   PubMed Web of Science ®Google Scholar
• Jakob E, Max R, Zimmermann S, et al. Three years of experience with QuantiFERON-TB gold testing in patients with uveitis. Ocul Immunol Inflamm. 2014;22(6):478–484. doi:10.3109/09273948.2013.866255.
   PubMed Web of Science ®Google Scholar
• Psilas K, Aspiotis M, Petroutsos G, Kalogeropoulos C, Constantopoulos S. Antituberculosis therapy in the treatment of peripheral uveitis. AnnOphthalmol. 1991;23:254–258.
   Web of Science ®Google Scholar
• Ang L, Kee A, Yeo TH, et al. Treatment outcome in patients with presumed tubercular uveitis at a tertiary referral eye care centre in Singapore. Int Ophthalmol. 2018;38(1):11–18. doi:10.1007/s10792-016-0401-6.
   PubMed Web of Science ®Google Scholar